Tertiary Gleason grades and consequent prognostic risk

We have known for a while that men with a tertiary Gleason grade of 4 or 5 (as  discussed below) are at heightened risk for progressive forms of prostate cancer. … READ MORE …

Prostate cancer news reports: Tuesday, April 20, 2010

In today’s news reports we note new articles dealing with:

  • Biopsy protocols, patient selection, and focal therapy
  • Tertiary Gleason pattern 4/5 and risk for progression post-RP
  • Evolving data on the uses of bisphosphonates and denosumab
  • SKIs in treatment of advanced forms of prostate cancer … READ MORE …

Treatment outcomes and the importance of Gleason pattern 5 in biopsy cores

D’Amico and colleagues have conducted a retrospective analysis of data from > 300 patients in an attempt to compare biochemical (PSA-based) outcomes of men with high-risk prostate cancer based on the presence or absence of any amount of Gleason pattern 5 cancer in their initial biopsy findings (as a primary, secondary, or tertiary pattern). The results emphasize the importance of the presence of tertiary Gleason pattern 5 tumor in patients with an overall Gleason score of 7. … READ MORE …

The meaning of tertiary Gleason pattern 5

Trpkov et al. have reported on recent findings related to the significance of a tertiary finding of Gleason pattern 5 prostate cancer in a biopsy core or cores from men diagnosed with prostate cancer of otherwise lower Gleason grade. In other words, what does it mean if a man should be diagnosed as having, for example, Gleason 4 + 3 = 7 disease (based on his two most extensive Gleason patterns being Gleason grade 4 and Gleason grade 3) but there is also a small amount of evident Gleason grade 5 cancer? … READ MORE …

What’s hot today? Tuesday, September 2

Today’s reports address:

  • The potential prognostic significance of a tertiary Gleason pattern in pathologic analysis of prostate cancer stage following a radical prostatectomy
  • The relative safety of two types of external beam radiotherapy in treatment of patients with localized prostate cancer … READ MORE …